REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO will join Baird and Morgan Stanley healthcare conferences, offering webcast access and 30-day replays for investors.

Rhea-AI Summary

REGENXBIO (RGNX) will participate in two upcoming healthcare investor conferences in New York in September 2026.

The company is scheduled for fireside chats at the Baird 2026 Global Healthcare Conference on Tuesday, September 15 at 8:30 a.m. ET, and at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16 at 8:30 a.m. ET. Live webcasts of select events will be accessible through the Investors section of REGENXBIO's website, with archived replays available for about 30 days after the events.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., Sept. 8, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

Baird 2026 Global Healthcare Conference
Fireside Chat: Tuesday, September 15 at 8:30 a.m. ET
Location: New York, NY 

Morgan Stanley 24th Annual Global Healthcare Conference
Fireside Chat: Wednesday, September 16 at 8:30 a.m. ET
Location: New York, NY

Live webcasts of select events can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. Archived replays of the webcasts will be available for approximately 30 days following the events.

ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA® and ITVISMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-302870539.html

SOURCE REGENXBIO Inc.

FAQ

How can investors access REGENXBIO's presentations at the upcoming conferences?

Live webcasts of select fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. Archived replays of the webcasts will remain available for approximately 30 days following the events.